Leishmania amazonensis (L. amazonensis)

Leishmania amazonensis is a species of parasitic protozoa belonging to the Leishmania mexicana complex, primarily distributed across the Amazon basin in South America. It is a major causative agent of American tegumentary leishmaniasis, a disease that manifests in several clinical forms ranging from simple localized cutaneous ulcers to severe, chronic diffuse cutaneous leishmaniasis (DCL) [PMID: 31412030]. The parasite's life cycle involves flagellated promastigotes transmitted by phlebotomine sandflies, which then transform into non-flagellated amastigotes within the phagolysosomes of host macrophages [PMID: 29020302]. While it is the causative agent of disease, 'Leishmania amazonensis' is an organism and not a specific molecular target (such as a receptor or enzyme); rather, it contains numerous potential therapeutic targets including trypanothione reductase and various cysteine proteases. Current treatment regimens rely on heavy metals or polyenes, which often suffer from high toxicity and increasing rates of clinical resistance [PMID: 30206140].

Other names

New World LeishmaniaLeishmania (Leishmania) amazonensis

Drugs targeting this organism typically act by disrupting the parasite's cell membrane (e.g., Amphotericin B binding to ergosterol), inhibiting DNA topoisomerases, or interfering with unique thiol metabolism pathways such as the trypanothione system [PMID: 30206140, PMID: 29535186].